Soufflé Therapeutics
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
$135MSeries B
ParticipantI
Invus
Activity from announced rounds
All recorded activity
Invus is the investment-firm name used by Encoded Therapeutics and in LifeMine transaction-counsel coverage.
Recorded funding activity
Encoded develops precision gene therapies for neurological disorders. LifeMine uses fungal genomes for drug discovery, while City develops RNA-interference medicines. The records identify different therapeutic approaches without substituting an unnamed parent or fund.
- Rounds participated in
- 9
- Confirmed lead rounds
- 0 6 roles undisclosed
- New companies
- 9 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.7B 8 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
9 in all activityPrecision Neuroscience
Develops a brain-computer interface intended to help people with paralysis operate digital devices.
$250MSeries D
ParticipantEncoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantLifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedCity Therapeutics
City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas.
$99.5MSeries B
Role not disclosedContraline
Develops hormonal and non-hormonal male contraceptives for men and couples globally
$92.5MSeries B
Role not disclosedFlexiv
Develops and manufactures adaptive robots for complex tasks
UndisclosedStrategic
Role not disclosedMirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosedParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosed